Pharmaceutical giant Novartis has announced plans to build a new manufacturing facility in Morrisville, North Carolina. This marks the seventh new site announced within a single year, completing the firm’s $23 billion investment roadmap for U.S.-based manufacturing and R&D.
Optimizing end-to-end production The 56,200-square-foot facility will focus on producing active pharmaceutical ingredients (APIs) for solid dosage tablets, capsules, and RNA therapeutics.
-
Manufacturing capability: The plant will enable Novartis to establish an “end-to-end” production flow, transitioning from active ingredients to finished medicines entirely within the U.S.
-
Regional presence: This project expands the company’s footprint in North Carolina to five facilities across three different sites, strengthening its local industrial base.
Strategic vision CEO Vas Narasimhan emphasized that building a connected, end-to-end footprint bolsters the company’s ability to locally develop, produce, and deliver medicines at scale. This strategy is designed to ensure timely access to medical innovation for American patients. With the Morrisville site, Novartis is on track to establish comprehensive manufacturing capabilities for all its advanced technology platforms in the United States.
Source: https://www.contractpharma.com/breaking-news/novartis-to-add-new-facility-in-morrisville-nc/